The complement component C5 is not responsible for the alternative pathway activity in rabbit erythrocyte hemolytic assays during eculizumab treatment

Cell Mol Immunol. 2020 Jun;17(6):653-655. doi: 10.1038/s41423-020-0406-y. Epub 2020 Mar 24.

Lambertus P van den Heuvel^{1

2

3}, Nicole C A J van de Kar¹, Caroline Duineveld⁴, Andrei Sarlea¹, Thea J A M van der Velden¹, Wilhelmus T B Liebrand¹, Sanne van Kraaij², Camilla Schjalm⁵, Romy Bouwmeester¹, Jack F M Wetzels⁴, Tom E Mollnes^{5

6

7}, Elena B Volokhina^{8

9}

¹ Department of Pediatric Nephrology Amalia Children's Hospital, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
² Department of Laboratory Medicine, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
³ Department of Pediatrics, University Hospitals Leuven, Leuven, Belgium.
⁴ Department of Nephrology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
⁵ Department of Immunology, Oslo University Hospital and University of Oslo, Oslo, Norway.
⁶ Research Laboratory, Nordland Hospital, Bodø, and K. G. Jebsen TREC, University of Tromsø, Tromsø, Norway.
⁷ Center of Molecular Inflammation Research, Norwegian University of Science and Technology, Trondheim, Norway.
⁸ Department of Pediatric Nephrology Amalia Children's Hospital, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands. Elena.Volokhina@radboudumc.nl.
⁹ Department of Laboratory Medicine, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands. Elena.Volokhina@radboudumc.nl.

No abstract available

Publication types